NOTCH1 and B-cell chronic lymphocytic leukemia: Analogously, the chemo-immunotherapy is not the best approach for cases with NOTCH1 mutations (that occur in approximately 10% of CLL patients at diagnosis, 20% at relapse and in over 30% of cases after Richter transformation) [83].